Controls (n = 50) | VF group (n = 50) | p value | |
---|---|---|---|
Matched characteristics | |||
Sex (male/female) | 48/2 | 48/2 | |
Age (years) | 58 (8) | 57 (8) | |
LV ejection fraction (%) | 41 (16) | 41 (18) | |
Number of diseased vessels | 2.4 (0.8) | 2.4 (0.7) | |
1/2/3 vessel CAD | 9/14/27 | 8/16/26 | |
Previous myocardial infarction | 39 | 39 | |
Inferior | 15 | 15 | |
Anterior | 13 | 13 | |
Multiple | 10 | 10 | |
Unknown | 1 | 1 | |
β Blockers during study ECG | 23 | 21 | |
Other characteristics | |||
History of hypertension | 19 | 21 | NS |
History of diabetes | 4 | 6 | NS |
NYHA class (I/II/III/IV) | 0/9/38/3 | 4/33/12/1 | < 0.001 |
Positive exercise test | 45 | 24 | < 0.001 |
Thrombolytic therapy | 17 | 6 | < 0.05 |
Previous CABG | 3 | 8 | NS |
Number of previous MIs | |||
0/1/2/3 | 11/25/10/3 | 11/29/5/4 | NS |
Left ventricular aneurysm | 2 | 12 | < 0.01 |
Left ventricular hypertrophy 1-150 | 7 | 5 | NS |
Medication during study ECG | |||
Digitalis | 12 | 13 | NS |
Diuretics | 15 | 20 | NS |
Calcium channel blockers† | 23 | 5 | < 0.001 |
Data are number of individuals or mean (SD).
↵1-150 SV1 + RV5 > 35 mm in the ECG;†Verapamil, diltiatzem or nifedipine.